$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000117184315004476 Filed on August 07, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$4.065M	$3.440M	$1.811M
YoY Change	-6.81%	89.95%	-36.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.710M	$7.660M	$1.790M
YoY Change	338.07%	327.93%	110.59%
% of Gross Profit
Research & Development	$16.35M	$9.690M	$9.298M
YoY Change	75.66%	4.22%	89.37%
% of Gross Profit
Depreciation & Amortization	$153.0K	$147.0K	$149.0K
YoY Change	9.29%	-1.34%	-0.67%
% of Gross Profit
Operating Expenses	$62.20M	$17.86M	$11.23M
YoY Change	454.89%	58.98%	89.76%
Operating Profit	-$58.14M	-$14.42M	-$9.423M
YoY Change	749.47%	53.03%
Interest Expense	$13.96M	-$470.0K	$3.340M
YoY Change	-893.18%	-114.07%	5466.67%
% of Operating Profit
Other Income/Expense, Net	$13.96M	-$466.0K
YoY Change
Pretax Income	-$44.18M	-$14.89M	-$6.080M
YoY Change	413.7%	144.84%	101.99%
Income Tax	-$15.20M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$28.98M	-$14.89M	-$6.081M
YoY Change	236.84%	144.8%	102.03%
Net Earnings / Revenue	-712.96%	-432.73%	-335.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$570.9K	-$274.4K	-$275.6K
COMMON SHARES
Basic Shares Outstanding	54.33M
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$196.1M	$207.2M	$117.2M
YoY Change	80.24%	76.79%	202.84%
Cash & Equivalents	$181.1M	$207.2M	$85.27M
Short-Term Investments	$15.00M	$0.00	$32.00M
Other Short-Term Assets	$1.200M	$1.800M	$400.0K
YoY Change	71.43%	350.0%	-90.48%
Inventory
Prepaid Expenses
Receivables	$2.600M	$6.332M	$500.0K
Other Receivables	$100.0K	$0.00	$0.00
Total Short-Term Assets	$200.0M	$215.7M	$118.2M
YoY Change	79.05%	82.49%	165.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.300M	$2.036M	$1.700M
YoY Change	43.75%	19.76%	21.43%
Goodwill		$156.1M
YoY Change
Intangibles		$390.0M
YoY Change
Long-Term Investments	$10.00M	$10.00M	$12.20M
YoY Change	-14.53%	-18.03%
Other Assets
YoY Change
Total Long-Term Assets	$522.6M	$558.1M	$13.90M
YoY Change	3800.0%	3915.24%	969.23%
TOTAL ASSETS
Total Short-Term Assets	$200.0M	$215.7M	$118.2M
Total Long-Term Assets	$522.6M	$558.1M	$13.90M
Total Assets	$722.6M	$773.8M	$132.1M
YoY Change	477.62%	485.78%	187.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.900M	$2.800M	$1.800M
YoY Change	-14.71%	55.56%	20.0%
Accrued Expenses	$4.300M	$3.800M	$2.000M
YoY Change	79.17%	90.0%	-41.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.80M	$16.13M	$16.40M
YoY Change	-29.23%	-1.64%	37.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.60M	$13.20M	$10.50M
YoY Change	34.65%	25.71%
Total Long-Term Liabilities	$13.60M	$13.20M	$10.50M
YoY Change	34.65%	25.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.80M	$16.13M	$16.40M
Total Long-Term Liabilities	$13.60M	$13.20M	$10.50M
Total Liabilities	$168.8M	$185.3M	$26.90M
YoY Change	470.27%	588.92%	126.05%
SHAREHOLDERS EQUITY
Retained Earnings		-$232.7M
YoY Change
Common Stock		$821.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$553.8M	$588.5M	$105.1M
YoY Change
Total Liabilities & Shareholders Equity	$722.6M	$773.8M	$132.1M
YoY Change	477.62%	485.78%	187.8%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$28.98M	-$14.89M	-$6.081M
YoY Change	236.84%	144.8%	102.03%
Depreciation, Depletion And Amortization	$153.0K	$147.0K	$149.0K
YoY Change	9.29%	-1.34%	-0.67%
Cash From Operating Activities	-$2.527M	-$16.67M	-$8.010M
YoY Change	-62.45%	108.13%	187.1%
INVESTING ACTIVITIES
Capital Expenditures	$589.0K	$383.0K	$246.0K
YoY Change	-492.67%	55.69%	-217.14%
Acquisitions
YoY Change
Other Investing Activities	-$17.14M	-$9.950M	-$42.99M
YoY Change	5810.34%	-76.86%
Cash From Investing Activities	-$17.73M	-$10.33M	-$43.24M
YoY Change	3840.67%	-76.12%	20489.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$2.000K	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$116.0K	$960.0K	234.0K
YoY Change	-83.19%	310.26%	234.29%
NET CHANGE
Cash From Operating Activities	-$2.527M	-$16.67M	-8.010M
Cash From Investing Activities	-$17.73M	-$10.33M	-43.24M
Cash From Financing Activities	$116.0K	$960.0K	234.0K
Net Change In Cash	-$20.14M	-$26.04M	-51.01M
YoY Change	210.39%	-48.96%	1641.09%
FREE CASH FLOW
Cash From Operating Activities	-$2.527M	-$16.67M	-$8.010M
Capital Expenditures	$589.0K	$383.0K	$246.0K
Free Cash Flow	-$3.116M	-$17.05M	-$8.256M
YoY Change	-52.64%	106.56%	220.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54328414
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015Q2	tkmr	Accrued Contract Revenue Percentage AccruedContractRevenuePercentage	0.025
CY2015Q2	tkmr	Accrued License Fee Accruals AccruedLicenseFeeAccruals
CY2014Q4	tkmr	Accrued License Fee Accruals AccruedLicenseFeeAccruals	250000
CY2015Q2	tkmr	Accrued Research And Development AccruedResearchAndDevelopment	1914000
CY2014Q4	tkmr	Accrued Research And Development AccruedResearchAndDevelopment	2391000
	tkmr	Cumulative Contribution For Product CumulativeContributionForProduct	2965000
	tkmr	Cumulative Contribution For Product CumulativeContributionForProduct	3702000
	tkmr	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	6607000
	tkmr	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	341000
CY2015Q2	tkmr	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	9.50
CY2014Q4	tkmr	Fair Value Of Warrants Outstanding Per Warrant FairValueOfWarrantsOutstandingPerWarrant	12.80
	tkmr	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	15000
	tkmr	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	-351000
	tkmr	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	7803000
	tkmr	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-801000
CY2004Q1	tkmr	Maximum Contribution For Product MaximumContributionForProduct	7179000
CY2004Q1	tkmr	Maximum Contribution For Product MaximumContributionForProduct	9323000
CY2015Q2	tkmr	Noncash Financial Or Equity Instrument Consideration Fair Value Of Warrants Exercised NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised
CY2014Q2	tkmr	Noncash Financial Or Equity Instrument Consideration Fair Value Of Warrants Exercised NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised	116000
	tkmr	Noncash Financial Or Equity Instrument Consideration Fair Value Of Warrants Exercised NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised
	tkmr	Noncash Financial Or Equity Instrument Consideration Fair Value Of Warrants Exercised NoncashFinancialOrEquityInstrumentConsiderationFairValueOfWarrantsExercised	116000
CY2004Q1	tkmr	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2015Q1	tkmr	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	142177000
	tkmr	Royaltyguarantees Commitments Percentage RoyaltyguaranteesCommitmentsPercentage	0.025
CY2015Q2	tkmr	Wholly Owned Subsidiaries WhollyOwnedSubsidiaries	5
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2802000
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2044000
CY2015Q2	tkmr	Wholly Owned Subsidiaries Included In Financial Statements WhollyOwnedSubsidiariesIncludedInFinancialStatements	4
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6920000
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9328000
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	13650000
CY2015Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	6332000
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1903000
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6332000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1903000
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	604000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1294000
CY2015Q2	us-gaap	Assets Assets	773820000
CY2014Q4	us-gaap	Assets Assets	118178000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	215702000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	116418000
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10433000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11199000
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-28264000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22313000
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27844000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26208000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7230000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2774398
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2558925
CY2015Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	217217000
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	112161000
CY2015Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	361000
CY2014Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	9656000
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts
CY2015Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	381942000
CY2015Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4736000
CY2015Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5136000
CY2015Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5136000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	15722000
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	2310000
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85267000
CY2015Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition
CY2014Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	324000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	207205000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72187000
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	232276000
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134357000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68717000
CY2015Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	207205000
CY2014Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	72187000
CY2015Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25071000
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-49090000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	135018000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16550000
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	379500
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	398250
CY2015Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54303402
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22438169
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54303402
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22438169
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	821660000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	290004000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11663000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2307000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32826000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22449000
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	1144000
	us-gaap	Contracts Revenue ContractsRevenue	5830000
	us-gaap	Contracts Revenue ContractsRevenue	4833000
	us-gaap	Depreciation Depreciation	283000
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent
CY2015Q2	us-gaap	Depreciation Depreciation	147000
CY2014Q2	us-gaap	Depreciation Depreciation	149000
	us-gaap	Depreciation Depreciation	267000
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5605000
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5779000
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8045000
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9937000
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	156007000
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2015Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	967000
CY2014Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1924000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-340000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-545000
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	491000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2873000
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P146D
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P182D
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.6932
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.8522
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1391000
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0059
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.01
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4418000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1332000
CY2015Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2024000
CY2014Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5813000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	801000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-7803000
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	-2571000
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	-2728000
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	4467000
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	-1285000
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2639000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7662000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1787000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10378000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3837000
CY2015Q2	us-gaap	Goodwill Goodwill	156053000
CY2014Q4	us-gaap	Goodwill Goodwill
CY2015Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	55000
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	86000
CY2015Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7351000
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-943000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5343000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	108000
CY2015Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1738000
CY2014Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1231000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4624000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	178000
CY2015Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities
CY2014Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	57000
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	112000
CY2015Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	334000
CY2014Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	455000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-957000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12744000
CY2015Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	519000
CY2014Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-243000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	298000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-725000
CY2015Q2	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-1304000
CY2014Q2	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-220000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-178000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-12000
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	390017000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	81000
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	257000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	283000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	404000
CY2014Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	39974000
CY2015Q2	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	364000
CY2014Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	250000
CY2015Q2	us-gaap	Liabilities Liabilities	185319000
CY2014Q4	us-gaap	Liabilities Liabilities	30143000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	773820000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118178000
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16131000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20206000
CY2015Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	8742000
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	5099000
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	1130000
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	667000
	us-gaap	Licenses Revenue LicensesRevenue	2292000
	us-gaap	Licenses Revenue LicensesRevenue	1408000
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	10012000
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments
CY2015Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	960000
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	234000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143780000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59523000
CY2015Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10327000
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43238000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27219000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43573000
CY2015Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16671000
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8010000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35641000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1145000
	us-gaap	Net Income Loss NetIncomeLoss	-26875000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-14886000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6081000
	us-gaap	Net Income Loss NetIncomeLoss	-24065000
CY2015Q2	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
CY2014Q2	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	381618000
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	17860000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	11234000
	us-gaap	Operating Expenses OperatingExpenses	40548000
	us-gaap	Operating Expenses OperatingExpenses	21622000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14420000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9423000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32426000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15381000
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	745000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	226000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5951000
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3223000
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3774000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1616000
CY2015Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	9944000
CY2014Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	42992000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-27419000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	42992000
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9700000
CY2015Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	383000
CY2014Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	246000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	524000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	581000
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1787000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1730000
CY2015Q2	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	25000
CY2014Q2	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	25000
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151875000
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000
CY2014Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142177000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56477000
CY2015Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	939000
CY2014Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	148000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1559000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2072000
CY2015Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	19000
CY2014Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	86000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	44000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	974000
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12469000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12959000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2036000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1760000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9690000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9298000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20247000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17502000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-232739000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-205864000
CY2015Q2	us-gaap	Revenues Revenues	3440000
CY2014Q2	us-gaap	Revenues Revenues	1811000
	us-gaap	Revenues Revenues	8122000
	us-gaap	Revenues Revenues	6241000
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22063438
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42297517
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20938503
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54255804
CY2015Q1	us-gaap	Share Price SharePrice	20.25
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	39974000
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7500000
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	381942000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	142177000
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	384000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1559000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	88035000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	588501000
CY2015Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	323000
CY2014Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	538000
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3606000
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5099000
CY2015Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	3606000
CY2014Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5099000
CY2013Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5379000
CY2014Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	6590000

Files In Submission

Name	View Source	Status
0001171843-15-004476-index-headers.html	Edgar Link	pending
0001171843-15-004476-index.html	Edgar Link	pending
0001171843-15-004476.txt	Edgar Link	pending
0001171843-15-004476-xbrl.zip	Edgar Link	pending
exh31_5.jpg	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_1010.htm	Edgar Link	pending
exh_1011.htm	Edgar Link	pending
exh_1012.htm	Edgar Link	pending
exh_1013.htm	Edgar Link	pending
exh_1014.htm	Edgar Link	pending
exh_102.htm	Edgar Link	pending
exh_103.htm	Edgar Link	pending
exh_104.htm	Edgar Link	pending
exh_105.htm	Edgar Link	pending
exh_106.htm	Edgar Link	pending
exh_107.htm	Edgar Link	pending
exh_108.htm	Edgar Link	pending
exh_109.htm	Edgar Link	pending
exh_31.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gfpf10q_080515.htm	Edgar Link	pending
image_001.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tkmr-20150630.xml	Edgar Link	completed
tkmr-20150630.xsd	Edgar Link	pending
tkmr-20150630_cal.xml	Edgar Link	unprocessable
tkmr-20150630_def.xml	Edgar Link	unprocessable
tkmr-20150630_lab.xml	Edgar Link	unprocessable
tkmr-20150630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2015 Q3 Form 10-Q Financial Statement

#000117184315004476 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2015 Q3 Form 10-Q Financial Statement

#000117184315004476 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus